Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epidermal growth factor receptor antagonists companion diagnostics - QIAGEN

Next Previous
Drug Profile

Epidermal growth factor receptor antagonists companion diagnostics - QIAGEN

Alternative Names: Afatinib (Tovok) companion diagnostic - QIAGEN; Afatinib companion diagnostic - QIAGEN; Anti-EGFR companion diagnostic - QIAGEN; Cetuximab (Erbitux) companion diagnostic - QIAGEN; Dacomitinib companion diagnostic - QIAGEN; KRAS Gene Mutation Analysis, Colorectal cancer (cetuximab); Panitumumab (Vectibix) companion diagnostic - QIAGEN; therascreen EGFR RGQ PCR Kit (afatinib); Therascreen EGFR test - QIAGEN; therascreen KRAS RGQ PCR Kit (panitumumab); Therascreen KRAS test - QIAGEN

Latest Information Update: 23 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator QIAGEN
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 18 Jan 2018 US FDA approves label extension of therascreen® KRAS RGQ PCR Kit to include EGFR mutations L681Q, G719X and S768I for Non-small cell lung cancer (Diagnosis)
  • 23 May 2014 Registered for Non-small cell lung cancer (diagnosis) in China
  • 23 May 2014 US FDA approves therascreen® KRAS RGQ PCR Kit as a companion diagnostic for panitumumab for first-line, combination treatment of metastatic Colorectal cancer in the USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top